Investor Presentaiton

27 MEDI0457 for HPV-Related Cancers in Partnership with AstraZeneca AstraZeneca $ INOVIO . MEDI0457 (formerly INO-3112) = VGX-3100 + INO-9012 (IL-12 plasmid) . • In 2015, AstraZeneca acquired exclusive rights to MEDI0457 · $27.5M upfront • ~$250M in potential development and commercial milestones . • Double-digit tiered royalties on MEDI0457 sales AstraZeneca is evaluating MEDI0457 in combination with its PD-L1 checkpoint inhibitor, durvalumab, in HPV-associated cancers INOVIO POWERING DNA MEDICINES

View entire presentation